University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck & Co. Inc.’s (NYSE:MRK) anti-PD ...

Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it.

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Merck MRK holds a strong foothold in the oncology space, propelled by its blockbuster PD-L1 inhibitor, Keytruda. The ...

A long-term analysis of patients with early-stage non-small cell lung cancer showed those who received radiation achieved ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Scientists have found a way to supercharge lung cancer treatment by transplanting healthy mitochondria into tumors, which both boosts immune response and makes chemotherapy far more effective. By ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...